The global genome editing market size was valued at USD 2.25 billion in 2015. Utilization of the technique in achievement of therapeutic genetic editing in infected cells and tissues, thereby removing deleterious mutations is anticipated to boost market with potential growth opportunities.
Genome editing technologies based on programmable nucleases such as zinc finger nucleases, and clustered regularly interspaced short palindromic repeat (CRISPR)-associated nuclease Cas9, and transcription activator-like effector nucleases, are responsible for growth with no signs of abatement of the technology in the coming years.
UK genome editing market, by end-use, 2014 - 2025 (USD Million)
Presence of strong pipeline products is also expected to impact industrial growth over the forecast period. Novel products are designed to aid in improvement of DNA targeting, with enhanced flexibility, specificity of the nuclease, and the ease of AAV packaging for delivery.
Utilization of this technique through a number of approaches such as correction in the deleterious mutations, disruption of viral DNA, or addition of therapeutic transgenes is expected to boost adoption.
Moreover, there has been significant interest in genome editing in the last few years and pharmaceutical and biotech companies have been racing to enter collaboration agreements with the emerging companies.
Companies are engaged in development of the products on their own and also by the virtue of strategic partnerships. Several companies are taking advantage of developments in DNA editing technology to develop products for non-medical purposes.
However, toxicity due to off-target effects of nucleases is still a safety concern for the market. In addition to this, the IP disputes pertaining to CRISPR technology amongst the industry players is anticipated to restrain growth in near future.
Given the novelty of the genome editing field, there are many opportunities to optimize the technology. CRISPR, ZFN, and TALENs/MegaTALs are the major technologies. PiggyBac, Flp-In, antisense and Jump-In are the other methods for gene editing and engineering.
CRISPR accounted for the largest share and is expected to dominate the market over the forecast period. Advantages associated with the use of technology such as it can be tailored to treat patient-specific mutations for the diseases such as cystic fibrosis are attributive for estimated share.
Genome editing market, by region, 2015 (USD Million)
Ease of control in DNA modification is responsible for the larger share of ex-vivo method of delivery. Furthermore, the strength and duration of nuclease expression can also be precisely regulated to maximize efficiency and minimize off-target editing.
Owing to the aforementioned advantages, CAR-t technology in the form of ex-vivo products in oncology blood disorders treatment are observed to be prioritized in therapeutic molecular scissors pipeline. However, large majority of diseases have to be treated by in vivo delivery as some specialized cells cannot be removed from body.
Application of this technology for cell line genetic engineering in the form of stem cell therapy and gene therapy accounted for the largest share and is anticipated to register lucrative growth.
Use of the technology for development of novel molecules that can be targeted for treating diseases such as hematological malignancies and infectious diseases is expected to drive the adoption of this technology in the coming years.
Amidst controversy, there is a potential growth for genome editing market in the field of animal genetic modification to understand gene function modification and tracking and expression analysis. Usage of molecular scissors in this vertical is also expected to drive demand over the forecast period.
Biotechnology organizations accounted for the largest share. Presence of large number of research projects carried out in gene engineering for development of novel therapeutics is responsible for the share. The other end-users for the technology include academic and government research institutions, and contract research organizations.
Academic and government research institutes are expected to witness fastest growth in the coming years owing to the rising adoption of the technology in university based projects. Introduction of advancements in the genome engineering sector is anticipated to accelerate its uptake in government research projects.
The solution opted by the market entities is provision of user-friendly kits and partial services to the stem cell researchers so that engineering can be performed themselves while maintaining required conditions for pluripotency. High cost associated with the development of infrastructure for the set-up of stem cell conditions for implementation is anticipated to restrain growth of the outsourcing services in the coming years.
Established companies such as Thermo Fisher and Sigma Aldrich Corporation are engaged in the provision of custom vectors for editing and engineering of cell lines. Outsourcing of these services is expected to increase in the coming years, thus boosting growth.
North America dominated the market in terms of revenue share owing to the higher adoption of advanced techniques in the research institutes based in the U.S. Furthermore, higher incidence of monogenic diseases in this region are attributive for the estimated share.
For instance, cystic fibrosis is a common, inherited disease that results in severe damage to the lungs and other organs and occurs at a frequency of 1 in 2,500 births in the U.S. Moreover, currently 122,000 people in the U.S. requiring an organ transplant, a number that is steadily increasing.
Accelerated research in the field of biotechnology and personalized medicine in the economies of Asia Pacific region is expected to boost growth over the forecast period. China is expected to witness fastest growth in this region.
Some of the prominent players operating in this vertical include Caribou Biosciences, Inc., Sangamo, Editas Medicine, Recombinetics, Inc, Thermo Fisher Scientific, Inc., CRISPR THERAPEUTICS, Intellia Therapeutics, Inc., and Sigma Aldrich Corporation.
Most of these companies take advantage of licenses from universities or other companies to use some of the DNA editing technologies. Many of these companies have products either on the market or are very close to launching a product.
The players are engaged in either in-house research or the acquisition of other companies or cross licensing agreements. Such agreements enable the licensing of new intellectual property based on novel proteins that may not be affected by disputes in order to continue development.
Base year for estimation
Actual estimates/Historical data
2014 & 2015
2016 - 2025
Revenue in USD Million and CAGR from 2016 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at regional & country level and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the genome editing market on the basis of technology, delivery method, application, end-use, service, and regions:
Technology Outlook (Revenue, USD Million; 2014 - 2025)
Delivery Method Outlook (Revenue, USD Million; 2014 - 2025)
Application Outlook (Revenue, USD Million; 2014 - 2025)
Cell Line Engineering
Animal Genetic Engineering
Plant Genetic Engineering
End-use Outlook (Revenue, USD Million; 2014 - 2025)
Biotechnology & Pharmaceutical Companies
Academic & Government Research Institutes
Contract Research Organizations
Service Outlook (Revenue, USD Million, 2014 - 2025)
Regional Outlook (Revenue, USD Million; 2013 - 2025)
Middle East and Africa (MEA)
b. The global genome editing market size was estimated at USD 3.8 billion in 2019 and is expected to reach USD 4.4 billion in 2020.
b. The global genome editing market is expected to grow at a compound annual growth rate of 13.7% from 2016 to 2025 to reach USD 8.2 billion by 2025.
b. North America dominated the genome editing market with a share of 48.0% in 2019. This is attributable to the higher adoption of advanced techniques in the research institutes based in the U.S. Furthermore, a higher incidence of monogenic diseases in this region is attributive for the estimated share.
b. Some key players operating in the genome editing market include Caribou Biosciences, Inc., Sangamo, Editas Medicine, Recombinetics, Inc, Thermo Fisher Scientific, Inc., CRISPR THERAPEUTICS, Intellia Therapeutics, Inc., and Sigma Aldrich Corporation.
b. Key factors that are driving the market growth include success in pre-clinical models drives demands for genome editing therapeutics, rising competition amongst market participants for business development, easy editing solutions for the development of therapeutics for a broad range of diseases, increasing demand for synthetic genes and genetically modified organisms, technological advancements in gene-editing technologies, and rising adoption in agricultural biotechnology.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.